Lilly Buys Centessa for $7.8 Billion to Fight Sleep Disorders
Eli Lilly is acquiring Centessa in a $7.8 billion deal to develop breakthrough OX2R drugs for narcolepsy, idiopathic hypersomnia, and excessive daytime sleepiness.
/ 3 items
#CNTA↓
Truist Says Alkermes’ Alixorexton Data Lacks Detail Despite Phase 2 Success
Truist comments on Alkermes’ Phase 2 Vibrance-2 trial of alixorexton in narcolepsy type 2, noting "limited" details but strong patient engagement and maintaining a Buy rating with a $50 target.
Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong
Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong.